Relmada Therapeutics annual stock-based compensation
2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Relmada Therapeutics Stock-Based Compensation Growth & History (RLMD)
Relmada Therapeutics's stock-based compensation was $13.9M for fiscal 2025.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13.9M | −$16.3M | −53.93% |
| 2024 | 2024-12-31 | $30.2M | −$13.6M | −31.10% |
| 2023 | 2023-12-31 | $43.8M | −$383,616 | −0.87% |
| 2022 | 2022-12-31 | $44.2M | $3.7M | +9.14% |
| 2021 | 2021-12-31 | $40.5M | $19.7M | +94.90% |
| 2020 | 2020-12-31 | $20.8M | $17.6M | +556.44% |
| 2019 · Dec 31 | 2019-12-31 | $3.2M | — | — |
| 2019 · Jun 30 | 2019-06-30 | $1.2M | $695,997 | +134.36% |
| 2018 | 2018-06-30 | $517,999 | −$186,453 | −26.47% |
| 2017 | 2017-06-30 | $704,452 | −$298,124 | −29.74% |
| 2016 | 2016-06-30 | $1.0M | $205,624 | +25.80% |
| 2015 | 2015-06-30 | $796,952 | −$9.5M | −92.28% |
| 2014 | 2014-06-30 | $10.3M | — | — |
| 2013 · Dec 31 | 2013-12-31 | $382,343 | $345,008 | +924.09% |
| 2012 · Dec 31 | 2012-12-31 | $37,335 | — | — |
Relmada Therapeutics quarterly stock-based compensation
Q3.13
Q4.13
Q1.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $902,903 | −$2.5M | −73.82% |
| Q1 2026 | 2026-03-31 | $956,186 | −$2.6M | −73.24% |
| Q4 2025 | 2025-12-31 | $2.4M | −$4.4M | −64.75% |
| Q3 2025 | 2025-09-30 | $4.5M | −$3.4M | −43.23% |
| Q2 2025 | 2025-06-30 | $3.4M | −$3.8M | −52.19% |
| Q1 2025 | 2025-03-31 | $3.6M | −$4.7M | −56.93% |
| Q4 2024 | 2024-12-31 | $6.7M | −$3.2M | −32.02% |
| Q3 2024 | 2024-09-30 | $7.9M | −$3.4M | −30.23% |
| Q2 2024 | 2024-06-30 | $7.2M | −$4.0M | −35.42% |
| Q1 2024 | 2024-03-31 | $8.3M | −$3.1M | −26.94% |
| Q4 2023 | 2023-12-31 | $9.9M | −$1.7M | −14.90% |
| Q3 2023 | 2023-09-30 | $11.4M | $3.0M | +36.55% |
| Q2 2023 | 2023-06-30 | $11.2M | −$1.1M | −9.15% |
| Q1 2023 | 2023-03-31 | $11.4M | −$576,215 | −4.83% |
| Q4 2022 | 2022-12-31 | $11.6M | −$6.7M | −36.68% |
| Q3 2022 | 2022-09-30 | $8.3M | $329,169 | +4.11% |
| Q2 2022 | 2022-06-30 | $12.3M | $4.0M | +48.70% |
| Q1 2022 | 2022-03-31 | $11.9M | $6.1M | +103.90% |
| Q4 2021 | 2021-12-31 | $18.4M | $15.2M | +475.44% |
| Q3 2021 | 2021-09-30 | $8.0M | $2.8M | +52.80% |
| Q2 2021 | 2021-06-30 | $8.3M | $965,863 | +13.23% |
| Q1 2021 | 2021-03-31 | $5.9M | $811,922 | +16.11% |
| Q4 2020 | 2020-12-31 | $3.2M | $1.6M | +98.27% |
| Q3 2020 | 2020-09-30 | $5.2M | $4.5M | +592.17% |
| Q2 2020 | 2020-06-30 | $7.3M | $6.9M | +1709.98% |
| Q1 2020 · Mar 31 | 2020-03-31 | $5.0M | $4.6M | +1176.78% |
| Q4 2019 | 2019-12-31 | $1.6M | $1.3M | +511.79% |
| Q1 2020 · Sep 30 | 2019-09-30 | $757,716 | $604,916 | +395.89% |
| Q4 2019 | 2019-06-30 | $403,459 | $250,633 | +164.00% |
| Q3 2019 | 2019-03-31 | $394,692 | $232,427 | +143.24% |
| Q2 2019 | 2018-12-31 | $263,044 | $129,006 | +96.25% |
| Q1 2019 | 2018-09-30 | $152,800 | $83,930 | +121.87% |
| Q4 2018 | 2018-06-30 | $152,826 | −$139,043 | −47.64% |
| Q3 2018 | 2018-03-31 | $162,265 | $53,706 | +49.47% |
| Q2 2018 | 2017-12-31 | $134,038 | $2,078 | +1.57% |
| Q1 2018 | 2017-09-30 | $68,870 | −$103,194 | −59.97% |
| Q4 2017 | 2017-06-30 | $291,869 | $137,050 | +88.52% |
| Q3 2017 | 2017-03-31 | $108,559 | −$167,984 | −60.74% |
| Q2 2017 | 2016-12-31 | $131,960 | −$155,750 | −54.13% |
| Q1 2017 | 2016-09-30 | $172,064 | −$111,440 | −39.31% |
| Q4 2016 | 2016-06-30 | $154,819 | −$42,057 | −21.36% |
| Q3 2016 | 2016-03-31 | $276,543 | $32,733 | +13.43% |
| Q2 2016 | 2015-12-31 | $287,710 | $89,434 | +45.11% |
| Q1 2016 | 2015-09-30 | $283,504 | $125,514 | +79.44% |
| Q4 2015 | 2015-06-30 | $196,876 | — | — |
| Q3 2015 | 2015-03-31 | $243,810 | $178,373 | +272.59% |
| Q2 2015 | 2014-12-31 | $198,276 | −$174,586 | −46.82% |
| Q1 2015 | 2014-09-30 | $157,990 | $148,509 | +1566.39% |
| Q1 2014 · Mar 31 | 2014-03-31 | $65,437 | — | — |
| Q4 2013 | 2013-12-31 | $372,862 | — | — |
| Q3 2013 | 2013-09-30 | $9,481 | — | — |
Relmada Therapeutics stock-based compensation trends
Over the last five fiscal years, Relmada Therapeutics's stock-based compensation decreased from $20.8M to $13.9M, a change of −$6.9M. The latest reported quarter, Q2 2026, shows $902,903.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics source filings ↗